Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 36
- Registration Number
- NCT05782374
- Locations
- 🇮🇹
Ospedale San Raffaele, Milan, Italy
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
- Conditions
- Interventions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05672173
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05564052
- Locations
- 🇹🇷
Ondokuz Mayis University, Atakum, Turkey
🇧🇷Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil
🇧🇷Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia, Brasilia, Brazil
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Oncternal Therapeutics, Inc
- Registration Number
- NCT05431179
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 394
- Registration Number
- NCT05283720
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States
🇺🇸Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 650
- Registration Number
- NCT05254743
- Locations
- 🇺🇸
Eisenhower Army Medical Center, Rancho Mirage, California, United States
🇺🇸Alta Bates Summit Medical Center, Berkeley, California, United States
🇺🇸Baylor Scott & White Health, Round Rock, Texas, United States
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT05211336
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Theodore S. Johnson
- Target Recruit Count
- 37
- Registration Number
- NCT05106296
- Locations
- 🇺🇸
Augusta University, Georgia Cancer Center, Augusta, Georgia, United States
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT05105841
- Locations
- 🇯🇵
National Cancer Center Hospital /ID# 232449, Chuo-ku, Tokyo, Japan
🇯🇵University Hospital Kyoto Prefectural University of Medicine /ID# 239883, Kyoto-shi, Kyoto, Japan
🇯🇵Tohoku University Hospital /ID# 238433, Sendai-shi, Miyagi, Japan
ECP Combination Study
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-03-28
- Target Recruit Count
- 319
- Registration Number
- NCT05052385
- Locations
- 🇧🇪
Antwerp University, Antwerp, Belgium
🇬🇷George Papanicolaou General Hospital, Thessaloníki, Greece
🇫🇷Institut de Cancerologie Lucien Neuwirth, Saint-Étienne, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.